Late-breaking results from the CONFIRM2 global multicenter study were presented today at the Transcatheter Cardiovascular Therapeutics (TCT) 2024 conference. The study highlighted how a non-invasive, comprehensive AI-based analysis of cardiac computed tomography (CT) can effectively predict serious heart-related events in patients exhibiting symptoms of coronary artery disease (CAD).
A groundbreaking study titled “Prognostic Value of AI-Guided Quantitative Coronary CT Angiography (AI-QCT) Technology in Patients with Suspected Coronary Artery Disease” was presented by Dr. Alexander R. van Rosendael, MD, PhD, from the Department of Cardiology at Leiden University Medical Center. The research identified key atherosclerotic features most closely linked to major adverse cardiovascular events (MACE), showing that these indicators outperform traditional clinical risk scores.
The study involved 3,551 symptomatic patients from 18 sites across 13 countries and utilized advanced AI technology to analyze coronary computed tomography angiography (CCTA) data. It found that the strongest predictors of MACE were: 1) % Diameter Stenosis and 2) Non-Calcified Plaque Volume. Interestingly, the study also revealed that coronary artery calcified plaque volume was not an independent predictor of adverse outcomes.
Dr. James K. Min, Founder and CEO of Cleerly, emphasized the research’s significance, stating, “The integration of AI in assessing coronary artery disease represents a transformative leap in our ability to predict and manage heart disease-related events. AI-QCT analysis provides precise diameter stenosis percentages and an accurate view of non-calcified plaque volume based on millions of images. This study not only highlights AI’s potential to enhance diagnostic accuracy but also underscores the importance of early intervention in mitigating serious cardiovascular risks.”
The findings indicate that AI-driven evaluations could guide treatment decisions, potentially improving outcomes for patients with coronary artery disease and reducing cardiovascular events.
About Cleerly
Cleerly is dedicated to eliminating heart attacks by establishing a new standard of care for heart disease. Through its FDA-cleared, AI-driven solutions, Cleerly facilitates comprehensive phenotyping of coronary artery disease using advanced non-invasive CT imaging. Grounded in science and based on millions of images from over 40,000 patients, Cleerly’s approach is supported by a world-class clinical and technical team, enhancing health literacy for all stakeholders in the coronary care pathway.
